Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Pim Sermsaksasithorn, Chanidapa Wongtada, Varin Chaaim, Yuda Chongpison & Pravit Asawanonda. (2022) On and off-label uses of interleukin-17 inhibitors for patients with plaque-type psoriasis in Thailand: a real-world study. Journal of Dermatological Treatment 33:7, pages 2963-2974.
Read now
Read now
Julia Berman, Victoria Furer, Mark Berman, Ofer Isakov, Devy Zisman, Amir Haddad & Ori Elkayam. (2021) Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population. Biologics: Targets and Therapy 15, pages 463-470.
Read now
Read now
Lluís Puig. (2020) The safety of ixekizumab in psoriasis drug therapy. Expert Opinion on Drug Safety 19:2, pages 117-130.
Read now
Read now
Christoffer Blegvad, Lone Skov & Claus Zachariae. (2019) Ixekizumab for the treatment of psoriasis: an update on new data since first approval. Expert Review of Clinical Immunology 15:2, pages 111-121.
Read now
Read now
Articles from other publishers (19)
Nikolai Loft, Alexander Egeberg, Daniel Isufi, Mads K. Rasmussen, Lars E. Bryld, Tomas N. Dam, Kawa K. Ajgeiy, Trine Bertelsen & Lone Skov. (2023) Response to Interleukin-17A Inhibitors According to Prior Biologic Exposures: A Danish Nationwide Study. Acta Dermato-Venereologica 103, pages adv12616.
Crossref
Crossref
Bruce Strober, Carle Paul, Andrew Blauvelt, Diamant Thaçi, Luis Puig, Mark Lebwohl, Katy White, Veerle Vanvoorden, Delphine Deherder, Natalie Nunez Gomez & Kilian Eyerich. (2023) Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial. Journal of the American Academy of Dermatology 89:3, pages 486-495.
Crossref
Crossref
Megumi Kishimoto, Mayumi Komine, Koji Kamiya, Junichi Sugai, Aya Kuwahara, Makiko Mieno & Mamitaro Ohtsuki. (2023) Drug Survival of Tumor Necrosis Factor-Alpha Inhibitors and Switched Subsequent Biologic Agents in Patients with Psoriasis: A Retrospective Study. Dermatology and Therapy 13:6, pages 1347-1360.
Crossref
Crossref
Jolijn C. Bethlem, Jenny A. H. M. Janssens & Milan Tjioe. (2023) Real‐world drug survival of Brodalumab, in patients with psoriasis switched from Ixekizumab: Results of a single centre retrospective study (BroSwitch). JEADV Clinical Practice.
Crossref
Crossref
Francesco Cavallo, Silvia Borriello, Luca Mastorino, Paolo Dapavo, Pietro Quaglino & Simone Ribero. (2023) Intraclass Switching among IL17 Inhibitors in Psoriasis: A Real-Life, Long-Term Single-Center Experience. Dermatologic Therapy 2023, pages 1-3.
Crossref
Crossref
Benjamin Lockshin, Ryan W. Harrison, Robert R. McLean, Margaux M. Crabtree, Bruce W. Konicek, Baojin Zhu, William N. Malatestinic, Bilal Atiya, Mwangi J. Murage & Russel T. Burge. (2022) Outcomes in Ixekizumab Patients Following Exposure to Secukinumab and Other Biologics in the CorEvitas Psoriasis Registry. Dermatology and Therapy 12:12, pages 2797-2815.
Crossref
Crossref
E. Sotiriou, K. Bakirtzi, I. Papadimitriou, A. Tsentemeidou, N. Kougkas, A. Panagopoulou, D. Ioannides & E. Vakirlis. (2022)
Real‐life intraclass switch among
IL
‐17 inhibitors in psoriasis: results from a single‐centre, 24‐week, retrospective study
. Journal of the European Academy of Dermatology and Venereology 36:11.
Crossref
Crossref
Martin Tichy, Martina Kojanova, Barbora Velackova, Tomas Dolezal, Spyridon Gkalpakiotis & Petra Cetkovska. (2022)
Efficacy of switches within the class of
IL
‐17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy (
BIOREP
)
. Dermatologic Therapy 35:10.
Crossref
Crossref
Rani Soenen, Zhigang Wang, Lynda Grine, Erwin Dreesen, Lisa Schots, Els Brouwers, Paul Declerck, Debby Thomas & Jo Lambert. (2022) Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis. Clinical and Experimental Dermatology 47:7, pages 1324-1336.
Crossref
Crossref
Marko Barešić, Ljiljana Smiljanić Tomičević, Branimir Anić & Miroslav Mayer. (2022) Successful IL-17A inhibitor cycling in psoriatic arthritis patient: a case report and a literature review. Rheumatology International 42:2, pages 365-370.
Crossref
Crossref
Frank Kolbinger, Franco Di Padova, Atul Deodhar, Jason E. Hawkes, Christine Huppertz, Torsten Kuiper, Iain B. McInnes, Christopher T. Ritchlin, David Rosmarin, Georg Schett, José M. Carballido, Peter Häusermann, Claudio Calonder, Beate Vogel, Jean-Michel Rondeau & Gerard Bruin. (2022) Secukinumab for the treatment of psoriasis, psoriatic arthritis, and axial spondyloarthritis: Physical and pharmacological properties underlie the observed clinical efficacy and safety. Pharmacology & Therapeutics 229, pages 107925.
Crossref
Crossref
B. Pinilla Martín, A. Sánchez Velázquez, C. Vico Alonso & R. Rivera Díaz. (2021) Switching From One Anti-IL-17 Antibody to Another: On Trying Again or Changing the Target. Actas Dermo-Sifiliográficas (English Edition) 112:5, pages 473-475.
Crossref
Crossref
B. Pinilla Martín, A. Sánchez Velázquez, C. Vico Alonso & R. Rivera Díaz. (2021) De un anti-IL-17 a otro: dar una segunda oportunidad o cambiar de diana. Actas Dermo-Sifiliográficas 112:5, pages 473-475.
Crossref
Crossref
Alan Menter, Gerald G. Krueger, So Yeon Paek, Dario Kivelevitch, Iannis E. Adamopoulos & Richard G. Langley. (2021) Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities. Dermatology and Therapy 11:2, pages 385-400.
Crossref
Crossref
Nikolai Loft, Anne-Sofie Halling, Alexander Egeberg & Lone Skov. (2021) Efficacy of a second interleukin 17 inhibitor in patients with psoriasis: A systematic review and meta-analysis. Journal of the American Academy of Dermatology 84:1, pages 130-138.
Crossref
Crossref
Esther von Stebut, Wolf-Henning Boehncke, Kamran Ghoreschi, Tommaso Gori, Ziya Kaya, Diamant Thaci & Andreas Schäffler. (2020) IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications. Frontiers in Immunology 10.
Crossref
Crossref
Kim Papp, Andrew Blauvelt, John Sullivan, Yayoi Tada, Paula Polzer, Lotus Mallbris, Lu Zhang & Chi-ho Hong. (2019) Ixekizumab—An Effective and Safe Treatment for Moderate-to-Severe Plaque Psoriasis in Patients Previously Treated With Other IL-17 Inhibitors: Results From IXORA-P. Journal of Psoriasis and Psoriatic Arthritis 4:4, pages 180-185.
Crossref
Crossref
A. Conti, F. Peccerillo, P. Amerio, A. Balato, F. Bardazzi, L. Bianchi, M. Burlando, S.P. Cannavò, A. Chiricozzi, P. Dapavo, C. De Simone, M.C. Fargnoli, A. Gambardella, P. Gisondi, P. Malagoli, G. Malara, C. Mugheddu, A.M. Offidani, S. Piaserico, F. Prignano, L. Stingeni & G. Pellacani. (2019) Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience. British Journal of Dermatology 180:6, pages 1547-1548.
Crossref
Crossref
Andreas Pinter, Dagmar Wilsmann‐Theis, Wiebke K. Peitsch & Rotraut Mössner. (2019)
Interleukin‐17 receptor
A
blockade with brodalumab in palmoplantar pustular psoriasis: Report on four cases
. The Journal of Dermatology 46:5, pages 426-430.
Crossref
Crossref